Human papillomavirus vaccination receipt and provider counseling rates among high-risk patients |
| |
| Institution: | 1. George Washington University Hospital, Department of Obstetrics and Gynecology, 900 23rd ST NW, Washington, DC 20037, United States;2. George Washington University, School of Medicine and Health Sciences, 2300 I St NW, Washington, DC 20052, United States;3. Sarasota Memorial Hospital, 1700 S Tamiami Trail, Sarasota, FL 34239, United States;1. College of Chemistry and Material Sciences, School of Life Sciences, Heilongjiang University, Harbin, Heilongjiang 150080, China;2. Institute of Nanobiomaterials and Immunology, Zhejiang Provincial Key Laboratory of Plant Evolutionary Ecology and Conservation, School of Life Sciences, Taizhou University, Taizhou 318000, China;1. Pfizer Vaccine Research and Development, 500 Arcola Rd, Collegeville, PA, USA;2. Vaccines, Antivirals and Evidence Generation, Pfizer Inc, 500 Arcola Rd, Collegeville, PA, USA;3. Pfizer Vaccine Clinical Research and Development, Horizon Building, Honey Lane, Hurley, SL6 6RJ, UK;1. Department of Paediatric Immunology and Rheumatology, Wilhelmina Children''s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands;2. Department of Pediatrics, Carmel Medical Center, Technion Faculty of Medicine, Haifa, Israel |
| |
| Abstract: | ObjectiveWe describe provider documented counseling patterns and perception regarding HPV vaccination among patients with a history of cervical dysplasia.MethodsAll patients ages 21–45 who underwent colposcopy at a single academic medical center from 2018 to 2020 were sent a self-administered survey through the electronic medical record patient portal to assess their attitudes regarding human papillomavirus (HPV) vaccination. Demographic information, HPV vaccination history, and documented obstetrics and gynecology provider counseling at the time of colposcopy were examined.ResultsOf 1465 patients, 434 (29.6 %) reported or had documented receipt of at least one dose of the human papillomavirus vaccine. The remainder reported they were not vaccinated or had no documentation of vaccination. Proportion of vaccinated patients was higher among White compared to Black and Asian patients (P = 0.02). On multivariate analysis, private insurance (aOR 2.2, 95 % CI 1.4–3.7) was associated with vaccinated status while Asian race (aOR 0.4, 95 % CI 0.2–0.7) and hypertension (aOR 0.2, 95 % CI 0.08–0.7) were less likely to be associated with vaccination status. Among patients with unvaccinated or unknown vaccination status, 112 (10.8 %) received documented counseling regarding catch-up human papillomavirus vaccination at a gynecologic visit. Patients seen by a sub-specialist obstetrics and gynecologic provider were more likely to have documented provider counseling regarding vaccination compared to those seen by a generalist obstetric/gynecologist provider (26 % vs 9.8 %, p < 0.001). Patients cited lack of physician discussion (53.7 %) and the belief that they were too old to receive the HPV vaccine (48.8 %) as the main reasons for remaining unvaccinated.ConclusionHPV vaccination and the rate of obstetric and gynecologic provider counseling regarding HPV vaccination among patients undergoing colposcopy remains low. When surveyed, many patients with a history of colposcopy cited provider recommendation as a factor in their decision to undergo adjuvant HPV vaccination, demonstrating the importance of provider counseling in this group. |
| |
| Keywords: | Human papillomavirus Cervical dysplasia Human papillomavirus 16 Human papillomavirus 18 Colposcopy Human papillomavirus vaccine CIN"} {"#name":"keyword" "$":{"id":"k0040"} "$$":[{"#name":"text" "_":"Cervical intraepithelial neoplasia |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
